Search results for "Monitoring"

showing 10 items of 3614 documents

Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma

2019

Almost all multiple myeloma (MM) cases have been demonstrated to be linked to earlier monoclonal gammopathy of undetermined significance (MGUS). Nevertheless, there are no identified characteristics in the diagnosis of MGUS that have been helpful in differentiating subjects whose cancer may progress to a malignant situation. Regarding malignancy, the role of lymphocyte subsets and cytokines at the beginning of neoplastic diseases is now incontestable. In this review, we have concentrated our attention on the equilibrium between the diverse lymphocyte subsets and the cytokine system and summarized the current state of knowledge, providing an overview of the condition of the entire system in …

0301 basic medicineT lymphocytesimmunosurveillanceReviewMalignancyMonoclonal Gammopathy of Undetermined SignificanceCatalysisInorganic Chemistrylcsh:Chemistry03 medical and health sciences0302 clinical medicineImmune systemSettore MED/43 - Medicina LegaleMonitoring ImmunologicGammopathycytokineMedicineHumansPhysical and Theoretical ChemistryMolecular Biologylcsh:QH301-705.5SpectroscopyMultiple myelomamonoclonal gammopathy of undetermined significance; multiple myeloma; T lymphocytes; cytokine; alarmin; inflammation; immunosurveillancebusiness.industryOrganic ChemistryCancerGeneral Medicinealarminmedicine.diseaseLymphocyte SubsetsComputer Science ApplicationsImmunosurveillancemultiple myeloma030104 developmental biologylcsh:Biology (General)lcsh:QD1-999inflammation030220 oncology & carcinogenesisImmunologyMonoclonalCytokinesbusinessMonoclonal gammopathy of undetermined significance
researchProduct

Validated HPLC-UV detection method for the simultaneous determination of ceftolozane and tazobactam in human plasma

2018

Aim: A simple, rapid, economical and sensitive HPLC-UV method was developed for the simultaneous quantification of ceftolozane and tazobactam in plasma samples. Methodology: After deproteinization followed by a liquid–liquid back-extraction, the compounds were separated on a C18 column (150 mm × 4.6 mm, 5 μm) with UV-visible detection at 220 nm. The mobile phase consisted of acetonitrile and potassium dihydrogenphosphate buffer at pH 3.0 (8:92, v/v), delivered isocratically at a flow rate of 1.0 ml/min and at a column oven temperature of 30°C. Cefepime was used as an internal standard. Results: Linearity was achieved in the concentration range of 0.50–100.00 μg/ml for ceftolozane and 0.25–…

0301 basic medicineTazobactam030106 microbiologyClinical BiochemistryPenicillanic Acid01 natural sciencesHigh-performance liquid chromatographyTazobactamAnalytical ChemistryPlasma03 medical and health sciencesmedicineHumansSample preparationGeneral Pharmacology Toxicology and PharmaceuticsChromatography High Pressure LiquidReproducibilityChromatographyPlasma samplesmedicine.diagnostic_testChemistry010401 analytical chemistryGeneral MedicineAnti-Bacterial AgentsCephalosporins0104 chemical sciencesMedical Laboratory TechnologyTherapeutic drug monitoringHuman plasmaCeftolozanemedicine.drugBioanalysis
researchProduct

Seasonal and spatial dynamics of enteric viruses in wastewater and in riverine and estuarine receiving waters

2018

International audience; Enteric viruses represent a global public health threat and are implicated in numerous foodborne andwaterborne disease outbreaks. Nonetheless, relatively little is known of their fate and stability in the environment. In this studywe used carefully validatedmethods tomonitor enteric viruses, namely adenovirus (AdV), JC polyomavirus (JCV), noroviruses (NoVs), sapovirus (SaV) and hepatitis A and E viruses (HAV and HEV) fromwastewater source to beaches and shellfish beds. Wastewater influent and effluent, surface water, sediment and shellfish samples were collected in the Conwy catchment (North Wales, UK) once a month for one year. High concentrations of AdV and JCV wer…

0301 basic medicineVeterinary medicineviruses010501 environmental sciencesWastewater01 natural sciencesWaste Disposal Fluid[SDV.IDA]Life Sciences [q-bio]/Food engineeringhuman adenovirusWaste Management and Disposalmurine norovirusbiologyhepatitis-eWaterborne diseasesvirus diseasesContaminationHepatitis EPollution6. Clean water3. Good healthqPCRWastewaterHealthdiverse microbes[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologySeasonsWater MicrobiologyTangential flow ultrafiltrationEnvironmental MonitoringPorcine gastric mucin assayEnvironmental Engineering030106 microbiologydrinking-waterblood group antigensViral survival03 medical and health sciencesEnteric virus trackingmedicineEnvironmental ChemistryEffluentShellfish0105 earth and related environmental scienceshuman polyomavirusviral gastroenteritisWater PollutionOutbreakSapovirusFaecal contaminationbiology.organism_classificationmedicine.diseaseBiology and Microbiologyporcine gastric mucinsimultaneous recovery
researchProduct

Invasion of Finnish inland waters by the alien moss animal Pectinatella magnifica Leidy, 1851 and associated potential risks

2018

Introduced alien species bring potential adverse impacts on biodiversity and ecosystem functions. International shipping is an important vector for such unintentional introductions in aquatic environments. Therefore, in addition to climate change and eutrophication, increasing international shipping may enhance the spread of alien species into areas which have not previously been considered prone to alien invasions. One example of such development might be the recent invasion of the moss animal Pectinatella magnifica into Finnish inland waters, which are generally considered to be hostile to alien species. We took advantage of observations made by the general public and recorded by environm…

0301 basic medicineinland watersEcologybiologyEcologyta1172vesiekosysteemitAlienManagement Monitoring Policy and Lawbiology.organism_classificationsisävedetPectinatella magnificaBryozoaintroduced species03 medical and health sciences030104 developmental biologysammaleläimetSuomiBryozoata1181vieraslajitEcology Evolution Behavior and SystematicsFinlandaquatic ecosystemsManagement of Biological Invasions
researchProduct

Maristem stem cells of marine/aquatic invertebrates: from basic research to innovative applications

2018

The “stem cells” discipline represents one of the most dynamic areas in biomedicine. While adult marine/aquatic invertebrate stem cell (MISC) biology is of prime research and medical interest, studies on stem cells from organisms outside the classical vertebrate (e.g., human, mouse, and zebrafish) and invertebrate (e.g., Drosophila, Caenorhabditis) models have not been pursued vigorously. Marine/aquatic invertebrates constitute the largest biodiversity and the widest phylogenetic radiation on Earth, from morphologically simple organisms (e.g., sponges, cnidarians), to the more complex mollusks, crustaceans, echinoderms, and protochordates. These organisms contain a kaleidoscope of MISC-type…

0301 basic medicinemarine/aquatic invertebratesQH301 Biologymarine/aquatic invertebrateBioactive moleculesT-NDASGeography Planning and Developmentlcsh:TJ807-830BiodiversitySettore BIO/05 - ZoologiaStem cellsblue biotechnology0302 clinical medicineBioactive moleculeBasic researchaging ; bioactive molecules ; blue biotechnology ; cancer ; cell culture ; COST Action ; Europe ; marine/aquatic invertebrates ; regeneration ; stem cellsGeneralLiterature_REFERENCE(e.g.dictionariesencyclopediasglossaries)lcsh:Environmental sciencesCancerlcsh:GE1-350quinonessea-urchin eggsStem cellGeographyPolicy and LawEcologylcsh:Environmental effects of industries and plantsManagementEuropeMarine/aquatic invertebrateStem cellCèl·lules mareEuropean communityMonitoringaging; bioactive molecules; blue biotechnology; cancer; cell culture; COST Action; Europe; marine/aquatic invertebrates; regeneration; stem cellslcsh:Renewable energy sourcesCOST ActionAging; Bioactive molecules; Blue biotechnology; Cancer; Cell culture; COST Action; Europe; Marine/aquatic invertebrates; Regeneration; Stem cells; Geography Planning and Development; Renewable Energy Sustainability and the Environment; Management Monitoring Policy and LawManagement Monitoring Policy and LawBiologyQH30103 medical and health sciencesSDG 3 - Good Health and Well-beingNear neighborunitsstem cellsbioactive moleculesevolutioncancerSDG 14 - Life Below WaterRenewable Energy14. Life underwaterSH Aquaculture. Fisheries. AnglingSHRegeneration (ecology)BiologyBiomedicineInvertebratePlanning and Developmentcell cultureScience & TechnologySustainability and the EnvironmentRenewable Energy Sustainability and the Environmentbusiness.industryMarine invertebratesagingInvertebrats marinsbioactive moleculecell_developmental_biology030104 developmental biologylcsh:TD194-19513. Climate actionregenerationproteinbusiness030217 neurology & neurosurgery
researchProduct

Early detection of gastric cancer beyond endoscopy - new methods

2021

Early detection of gastric cancer is remaining a challenge. This review summarizes current knowledge on non-invasive methods that could be used for the purpose. The role of traditional cancer markers such as CEA, CA 72-4, CA 19-9, CA 15-3, and CA 12-5 lies mainly in therapy monitoring than early detection. Most extensive studied biomarkers (pepsinogens, ABC method) are aiming at the detection of precancerous lesions with modest sensitivity for cancer. Tests based on the detection of cancer-specific methylation patterns (PanSeer), circulating proteins and mutations in circulating tumour DNA (CancerSEEK), as well as miRNA panels have demonstrated promising results bringing those closer to pra…

0301 basic medicinemedicine.diagnostic_testbusiness.industryGastroenterologyEarly detectionCancerEndoscopymedicine.diseaseSurvival AnalysisExtracellular vesiclesEndoscopy03 medical and health sciences030104 developmental biology0302 clinical medicineStomach Neoplasms030220 oncology & carcinogenesismicroRNACancer researchHumansMedicineTherapy monitoringbusinessEarly Detection of CancerBest Practice & Research Clinical Gastroenterology
researchProduct

Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD)

2018

Abstract Background Acid sphingomyelinase deficiency (ASMD), a rare lysosomal storage disease, results from mutations in SMPD1, the gene encoding acid sphingomyelinase (ASM). As a result, sphingomyelin accumulates in multiple organs including spleen, liver, lung, bone marrow, lymph nodes, and in the most severe form, in the CNS and peripheral nerves. Clinical manifestations range from rapidly progressive and fatal infantile neurovisceral disease, to less rapidly progressing chronic neurovisceral and visceral forms that are associated with significant morbidity and shorter life span due to respiratory or liver disease. Objectives To provide a contemporary guide of clinical assessments for di…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismDisease030105 genetics & heredityBiochemistryArticle03 medical and health sciencesLiver disease0302 clinical medicineEndocrinologyQuality of lifeInternal medicineGeneticsmedicineLysosomal storage diseaseHumansEnzyme Replacement TherapyMolecular BiologyMonitoring PhysiologicPatient monitoringClinical Trials as TopicAcid sphingomyelinase deficiencyASMDLungbusiness.industryDisease ManagementEnzyme replacement therapyNiemann-Pick Disease Type Amedicine.diseasePhenotypemedicine.anatomical_structureMutationPractice Guidelines as TopicQuality of LifeBone marrowAcid sphingomyelinasebusinessRisk Reduction Behavior030217 neurology & neurosurgerymedicine.drugMolecular Genetics and Metabolism
researchProduct

European Guidelines (S1) on the use of high‐dose intravenous immunoglobulin in dermatology

2016

Background The treatment of severe dermatological autoimmune diseases and toxic epidermal necrolysis (TEN) with high-dose intravenous immunoglobulin (IVIg) is a well-established procedure in dermatology. As treatment with IVIg is usually considered for rare clinical entities or severe clinical cases, the use of immunoglobulin is not generally based on data from randomized controlled trials that are usually required for the practice of evidence-based medicine. Owing to the rarity of the indications for the use of IVIg, it is also unlikely that such studies will be available in the foreseeable future. Because the high costs of IVIg treatment also limit its first-line use, the first clinical g…

0301 basic medicinemedicine.medical_specialtyMEDLINEHigh dose intravenous immunoglobulin610 Medicine & healthEuropean Guidelines (S1) high-dose intravenous immunoglobulinDermatologySkin DiseasesDrug Administration Schedulelaw.inventionAutoimmune Diseases2708 Dermatology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled triallawhemic and lymphatic diseasesintravenous immunoglobulinmedicineHumanshigh-doseEvidence-Based MedicineDose-Response Relationship Drugbusiness.industryDermatological diseases10177 Dermatology ClinicImmunoglobulins Intravenous2725 Infectious DiseasesEvidence-based medicinemedicine.diseaseDermatologyToxic epidermal necrolysisEuropeInfectious Diseases030104 developmental biologyEuropean Guidelines (S1)Dermatology clinicStevens-Johnson SyndromeInjections IntravenousEuropean Guidelines (S1) high-dose intravenous immunoglobulin dermatologyDrug MonitoringbusinessJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure

2020

In order to limit 5-fluorouracil (5-FU) toxicity, some health agencies recommend evaluating dihydropyrimidine dehydrogenase (DPD) deficiency before any 5-FU treatment introduction. In our study, we investigated relationships between 5-FU clearance and markers of DPD activity such as uracilemia (U), dihydrouracilemia (UH2)/U ratio, or genotype of the gene encoding DPD (DPYD). All patients with gastrointestinal cancers who received 5-FU-based regimens form March 2018 to June 2020 were included in our study. They routinely benefited of a pre-therapeutic DPYD genotyping and phenotyping. During 5-FU infusion, blood samples were collected to measure 5-FU steady-state concentration in order to ada…

0301 basic medicinemedicine.medical_specialtyUH2/U ratioFOLFIRINOXtherapeutic drug monitoringuracilemiaPharmaceutical Sciencelcsh:Medicinelcsh:RS1-441GastroenterologyArticlelcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicineDrug DiscoveryDihydropyrimidine dehydrogenaseMedicine5-FUmedicine.diagnostic_testbusiness.industrylcsh:RDPDmedicine.diseasePrimary tumorGI cancer030104 developmental biologyDocetaxelTherapeutic drug monitoring030220 oncology & carcinogenesisToxicityUH<sub>2</sub>/U ratioMolecular MedicineDPYDbusinesspharmacokineticsmedicine.drugPharmaceuticals
researchProduct

Vacuolated PAS-Positive Lymphocytes on Blood Smear: An Easy Screening Tool and a Possible Biomarker for Monitoring Therapeutic Responses in Late Onse…

2018

Background: Primary aim was to investigate the diagnostic value of PAS-positive vacuolated lymphocytes on blood smear in Late Onset Pompe Disease (LOPD) patients and, secondly, to evaluate its potential utility in monitoring treatment effects.Methods: We examined blood smear of 26 LOPD patients. We evaluated 10 treated and 16 untreated LOPD patients. Among the latter group, 7 patients later initiated ERT and were tested again 6 months after start. Blood smear was also sampled from 82 controls and 19 patients with other muscle glycogenoses (MGSDs). PAS staining was used to evaluate: (1) presence of lymphocytes with glycogen-filled vacuoles, (2) quantification of vacuolated lymphocytes.Result…

0301 basic medicinemedicine.medical_specialtytherapeutic monitoringBlood smear; LOPD screening test; PAS-positive lymphocytes; Pompe disease; Therapeutic monitoring; Neurology; Neurology (clinical)Late onsetPeriodic acid–Schiff stainDiseasePAS-positive lymphocytesGastroenterologylcsh:RC346-429Vacuolated Lymphocytes03 medical and health sciences0302 clinical medicineInternal medicineBlood smear; LOPD screening test; PAS-positive lymphocytes; Pompe disease; Therapeutic monitoringmedicineScreening toolLOPD screening testlcsh:Neurology. Diseases of the nervous systemOriginal Researchbusiness.industryPompe diseasePredictive value030104 developmental biologyBlood smearNeurologyblood smearBiomarker (medicine)Neurology (clinical)business030217 neurology & neurosurgeryFrontiers in neurology
researchProduct